EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
Authors:
- Denise A. YardleyDYDenise A. Yardley
- Robert WeaverRWRobert Weaver
- Michelle E. MeliskoMMMichelle E. Melisko
- Mansoor N. SalehMSMansoor N. Saleh
- Francis P. ArenaFAFrancis P. Arena
- Andres ForeroAFAndres Forero
- Tessa CiglerTCTessa Cigler
- Alison StopeckASAlison Stopeck
- Dennis CitrinDCDennis Citrin
- Ira OliffIOIra Oliff
- Rebecca BechholdRBRebecca Bechhold
- Randa LoutfiRLRanda Loutfi
- 10 May 2015
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (14) , 1609-1619
Abstract
Purpose: Glycoprotein NMB (gpNMB), a negative prognostic marker, is overexpressed in multiple tumor types. Glembatumumab vedotin is a gpNMB-specific monoclonal antibody conjugated to the potent cytotoxin monomethyl auristatin E. This phase II study investigated the activity of glembatumumab vedotin in advanced breast cancer by gpNMB expression. Patients and Methods: Patients (n = 124) with refractory breast cancer that expressed gpNMB in ≥ 5% of epithelial or stromal cells by central immunohistochemistry were stratified by gpNMB expression (tumor, low stromal intensity, high stromal intensity) and were randomly assigned 2:1 to glembatumumab vedotin (n = 83) or investigator's choice (IC) chemotherapy (n = 41). The study was powered to detect overall objective response rate (ORR) in the glembatumumab vedotin arm between 10% (null) and 22.5% (alternative hypothesis) with preplanned investigation of activity by gpNMB distribution and/or intensity (Stratum 1 to Stratum 3). Results: Glembatumumab vedotin was well tolerated as compared with IC chemotherapy (less hematologic toxicity; more rash, pruritus, neuropathy, and alopecia). ORR was 6% (five of 83) for glembatumumab vedotin versus 7% (three of 41) for IC, without significant intertreatment differences for predefined strata. Secondary end point revealed ORR of 12% (10 of 83) versus 12% (five of 41) overall, and 30% (seven of 23) versus 9% (one of 11) for gpNMB overexpression (≥ 25% of tumor cells). Unplanned analysis showed ORR of 18% (five of 28) versus 0% (0 of 11) in patients with triple-negative breast cancer (TNBC), and 40% (four of 10) versus 0% (zero of six) in gpNMB-overexpressing TNBC. Conclusion: Glembatumumab vedotin is well tolerated in heavily pretreated patients with breast cancer. Although the primary end point in advanced gpNMB-expressing breast cancer was not met for all enrolled patients (median tumor gpNMB expression, 5%), activity may be enhanced in patients with gpNMB-overexpressing tumors and/or TNBC. A pivotal phase II trial (METRIC [Metastatic Triple-Negative Breast Cancer]) is underway.Keywords
This publication has 16 references indexed in Scilit:
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced MelanomaJournal of Clinical Oncology, 2014
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast CancerJournal of Clinical Oncology, 2014
- Glycoprotein nonmetastatic B as a prognostic indicator in small cell lung cancerAPMIS, 2013
- ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic PropertiesPLOS ONE, 2010
- Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast CancerClinical Cancer Research, 2010
- Osteoactivin Promotes Breast Cancer Metastasis to BoneMolecular Cancer Research, 2007
- Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients with Glioblastoma MultiformeClinical Cancer Research, 2006
- CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.Clinical Cancer Research, 2006
- Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, l-amino acid-defined diet, accelerates motility of hepatoma cellsJournal of Hepatology, 2003
- Bone-related Genes Expressed in Advanced Malignancies Induce Invasion and Metastasis in a Genetically Defined Human Cancer ModelJournal of Biological Chemistry, 2003